Effect of 12 mg vs 6 mg of Dexamethasone in Adults With COVID-19 and Severe Hypoxemia

In a 2021 randomized trial of patients with COVID-19 and severe hypoxemia, 12 mg of dexamethasone did not statistically significantly reduce the number of days patients were alive without life support at 28 days compared with 6 mg of dexamethasone. In this video, Sheila Myatra, MD (Homi Bhabha National Institute, Mumbai, India), Balasubramanian Venkatesh, MD (The George Institute for Global Health, Sydney, Australia) and Anders Perner, MD, PhD (Rigshospitalet, Copenhagen, Denmark) present findings from the COVID STEROID 2 Trial at a Critical Care Reviews livestream presentation on October 21, 2021. An oral editorial, author reply to the oral editorial, a Q&A session, and a panel discussion follow. Go to https://ja.ma/3ERPse6 for full trial details.